DBD stock forecast, quote, news & analysis
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries... Show more
Diebold Nixdorf (DBD) Stock Analysis: Momentum Builds on Earnings Strength
Key Takeaways
- Diebold Nixdorf reported Q4 2025 adjusted EPS of $3.02, beating estimates by $1.30, with revenue up 2% year-over-year on 17% order entry growth.
- Raised 2026 guidance projects EPS of $5.25–$5.75 and revenue of $3.86–$3.94 billion, surpassing consensus expectations.
- Launched new $200 million share buyback after completing $100 million program, signaling confidence in valuation.
- Stock up 15% over recent 30 days and 72% over the past year, trading around $80 with analyst targets at $100.
- Credit upgrades and operational efficiencies support margin expansion amid shift to digital banking solutions.
Current Market Snapshot
Diebold Nixdorf (DBD) stock has shown robust momentum in recent trading sessions, reflecting investor approval of operational improvements and strategic capital returns. Shares have climbed significantly over the past year, with accelerated gains in recent weeks tied to strong financial results and optimistic guidance. Trading near multi-year highs around $80, the stock benefits from heightened search interest and positive analyst revisions. Broader market dynamics in financial technology and retail automation favor the company's positioning, though elevated valuations relative to peers warrant monitoring service margins and execution risks in a competitive landscape.
Recent Developments Driving DBD Price Action
Diebold Nixdorf's stock has experienced notable upward pressure in recent weeks, primarily propelled by its fiscal Q4 and full-year 2025 earnings release around mid-February 2026. The company delivered adjusted earnings per share of $3.02, substantially exceeding the consensus estimate of $1.72, while revenue reached $1.1 billion, marking a 2% year-over-year increase fueled by a robust 17% rise in order entry. These results underscored progress in higher-margin segments like banking automation and retail point-of-sale systems, with full-year adjusted EPS more than doubling year-over-year due to enhanced operational efficiency.
The earnings announcement triggered an immediate 6% share price surge, extending a 15% gain over the prior 30 days and contributing to a 72% one-year total return. Reinforcing this momentum, Diebold Nixdorf raised its fiscal 2026 guidance, forecasting EPS between $5.25 and $5.75—above the $5.02 consensus—and revenue in the $3.86 billion to $3.94 billion range, slightly ahead of expectations. Management highlighted record free cash flow generation and net income improvements, alongside the completion of a $100 million share repurchase program in Q4 2025, which reduced outstanding shares by about 6% for the full year.
Capitalizing on this strength, the company authorized a new $200 million buyback, signaling strong balance sheet confidence. Credit rating upgrades further bolstered sentiment, reflecting reduced leverage from restructuring efforts, including OpEx rationalization, repair center consolidations, and a pivot toward digital banking and contactless solutions. Analyst reactions were swift and supportive: On February 13, 2026, Wedbush set a $100 price target, while DA Davidson raised theirs from $80 to $100, maintaining Buy ratings. Weiss Ratings upgraded to Buy on February 17. These moves align with a consensus Strong Buy rating and $100 average target, implying over 20% upside from recent levels around $80.
Additional catalysts included reports of Arena Capital selling $35 million in shares, potentially viewed as non-core exit amid the stock's rally, and broader recognition of retail segment growth with 8% revenue increases and margin gains. These developments have shifted sentiment positively, though investors note pressures from hardware-to-software transitions impacting service margins and macroeconomic tariff risks.
2026 Outlook and Key Factors to Monitor
As Diebold Nixdorf advances into 2026, focus will center on executing raised guidance amid evolving demands in banking and retail automation. Projected revenue growth and doubled EPS targets hinge on sustained order momentum, projected free cash flow near $248 million, and margin expansion from lean initiatives and digital shifts like DN Vynamic software platforms. Opportunities lie in contactless payments and self-service trends, bolstered by the new buyback and deleveraging. However, investors should track competitive pricing pressures, supply chain stability, foreign exchange volatility, and potential tariff impacts on hardware costs. Regulatory scrutiny in financial tech and the pace of branch digitization will shape positioning against peers. Balanced execution across Banking and Retail segments remains pivotal for realizing consensus upside.
Momentum Indicator for DBD turns positive, indicating new upward trend
DBD saw its Momentum Indicator move above the 0 level on June 18, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 49 similar instances where the indicator turned positive. In of the 49 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
DBD moved above its 50-day moving average on May 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DBD crossed bullishly above the 50-day moving average on June 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in of 202 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 168 cases where DBD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 40 cases where DBD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for DBD turned negative on July 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DBD broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DBD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.806) is normal, around the industry mean (25.888). P/E Ratio (28.579) is within average values for comparable stocks, (73.594). DBD's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.394). Dividend Yield (0.000) settles around the average of (0.051) among similar stocks. P/S Ratio (0.789) is also within normal values, averaging (52.457).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PackagedSoftware